Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Summary

This is an open-label, single-dose, sequentially designed, single-period study to determine the effect of moderate renal impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.

Timeline

Start

2022-06-06

Primary completion

2022-10-20

Completion

2022-10-27

Drugs

Indications